Industry Seeks CMS Guidance On Preclinical Meetings, Trial Design
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidance on trial designs and communications between industry and CMS in the early stages of product development would clarify what evidence will be needed for national coverage decisions, Amgen and Guidant reps say. Such meetings may need to occur as early as the preclinical stage.